Quantitative study of controlled substance bedside wasting, disposal and evaluation of potential ecologic effects

Science of the Total Environment

Volumn 444, Issue , 2013, Pages 298-310

  Mankes, Russell F ^a   Silver, Charles D ^b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b The Capitol   (United States)

Author keywords

Controlled substances; Hazardous waste; Hospitals; Narcotics; Wastewater

Indexed keywords

DRUG PRODUCTS; HAZARDS; HOSPITALS; PHYSIOLOGY;

CONTROLED SUBSTANCE; DIRECT DISPOSAL; DRUG METABOLISMS; ECOTOXICITY; HAZARDOUS WASTES; HEALTHCARE FACILITY; MIDAZOLAM; NARCOTIC; QUANTITATIVE STUDY; TESTOSTERONE;

CONTROLLED DRUG DELIVERY;

ALPRAZOLAM; COCODAMOL; CONTROLLED SUBSTANCE; DIAZEPAM; FENTANYL; FENTANYL CITRATE; HYDROCODONE; HYDROCODONE BITARTRATE PLUS PARACETAMOL; HYDROCODONE PLUS PARACETAMOL; HYDROMORPHONE; KETAMINE; MIDAZOLAM; MORPHINE; MORPHINE SULFATE; NALBUPHINE; OXYCODONE; OXYCODONE PLUS PARACETAMOL; PARACETAMOL; PERCOCET; PETHIDINE; TESTOSTERONE; UNCLASSIFIED DRUG; ZOLPIDEM; ZOLPIDEM TARTRATE;

DRUG; ECOTOXICOLOGY; ENVIRONMENTAL IMPACT; HEALTH CARE; HOSPITAL SECTOR; POLLUTION EFFECT; QUANTITATIVE ANALYSIS; TOXICITY; WASTE DISPOSAL; WASTEWATER;

AQUATIC ENVIRONMENT; ARTICLE; DRUG EXCRETION; DRUG METABOLISM; ECOTOXICITY; ENVIRONMENTAL IMPACT ASSESSMENT; HEALTH CARE FACILITY; HOSPITAL PHARMACY; HOSPITAL WASTE; LC 50; LIQUID; NONHUMAN; PILL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TABLET; UNITED STATES; UNIVERSITY HOSPITAL; WASTE WATER DISPOSAL; WASTE WATER MANAGEMENT; WATER ANALYSIS;

ALBANY [NEW YORK]; NEW YORK [UNITED STATES]; UNITED STATES;

EID: 84871821032     PISSN: 00489697     EISSN: 18791026     Source Type: Journal    
DOI: 10.1016/j.scitotenv.2012.11.096     Document Type: Article

References (140)

1. The Merck veterinary manual 2012, Merck & Company, Whitehouse Station, NJ. 10th ed. S.E. Aiello, M.A. Moses (Eds.).
2. Aley K.O., Levine J.D. Dissociation of tolerance and dependence for opioid peripheral antinociception in rats. J Neurosci 1997, 17(10):3907-3912.
3. Ankley G.T., Jensen K.M., Kahl M.D., Makynen E.A., Blake L.S., Greene K.J., et al. Ketoconazole in the fathead minnow (Pimephales promelas): reproductive toxicity and biological compensation. Environ Toxicol Chem 2007, 26(6):1214-1223.
4. Armstrong S.C., Cozza K.L. Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, Part II. Psychosomatics 2003, 44(6):515-520. [Nov-Dec].
5. Ascalone V., Flaminio L., Guinebault P., Thénot J.P., Morselli P.L. Determination of zolpidem, a new sleep-inducing agent, and its metabolites in biological fluids: pharmacokinetics, drug metabolism and overdosing investigations in humans. J Chromatogr 1992, 581:237-250.
6. Ashton D., Hilton M., Thomas K.V. Investigating the environmental transport of human pharmaceuticals to streams in the United Kingdom. Sci Total Environ 2004, 333:167-184.
7. Baldacci A., Thormann W. Capillary electrophoresis contributions to the hydromorphone metabolism in man. Electrophoresis 2006, 27(12):2444-2457. [Jun].
8. Barakat N.H., Atayee R.S., Best B.M., Pesce A.J. Relationship between the concentration of hydrocodone and its conversion to hydromorphone in chronic pain patients using urinary excretion data. J Anal Toxicol 2012, 36(4):257-264. [May].
9. Barnes K.K., Kolpin D.W., Furlong E.T., Zaugg S.D., Meyer M.T., Barber L.B. A national reconnaissance of pharmaceuticals and other organic wastewater contaminants in the United States - I) Groundwater. Sci Total Environ 2008, 402:192-200.
10. Becker J., Mendez-Quigley T., Phillips M. Nursing role in the pharmaceutical life cycle. Nurs Adm Q 2010, 34(4):297-305.
11. Besse J.P., Latour J.F., Garric J. Anticancer drugs in surface waters: what can we say about the occurrence and environmental significance of cytotoxic, cytostatic and endocrine therapy drugs?. Environ Int 2012, 39(1):73-86. [Feb, Epub 2011 Nov 8].
12. Boleda M.R., Galceran M.T., Ventura F. Monitoring of opiates, cannabinoids and their metabolites in wastewater, surface water and finished water in Catalonia, Spain. Water Res 2008, 43:1126-1136.
13. Boxall A.B.A., Fogg L.A., Blackwell P.A., Kay P., Pemberton E.J., Croxford A. Veterinary medicines in the environment. Rev Environ Contam Toxicol 2003, 180:2-91.
14. Boxall A.B., Rudd M.A., Brooks B.W., Caldwell D.J., Choi K., Hickmann S., et al. Pharmaceuticals and personal care products in the environment: what are the big questions?. Environ Health Perspect 2012, 120(9):1221-1229. [Sep, Epub 2012 May 18].
15. Brain R.A., Johnson D.J., Richards S.M., Hanson M.L., Sanderson H., Lam M.W., et al. Microcosm evaluation of the effects of an eight pharmaceutical mixture to aquatic macrophytes Lemma gibba and Myriophyllum sibiricam. Aquat Toxicol 2004, 70:23-40.
16. Brown K.D., Kulis J., Thomson B., Chapman T.H., Mawhinney D.B. Occurrence of antibiotics in hospital, residential, and dairy effluent, municipal wastewater, and the Rio Grande in New Mexico. Sci Total Environ 2006, 366:772-783.
17. Bruce G.M., Pleus C.R., Snyder S.S. Toxicological relevance of pharmaceuticals in drinking water. Environ Sci Technol 2010, 44:5619-5626.
18. Bruchet A., Hochereau C., Picard C., Decottignies V., Rodriguez J.M., Janex-Habibi M.L. Analysis of drugs and personal care products in French source and drinking waters: the analytical challenge and examples of application. Water Sci Technol 2005, 52(8):53-61.
19. Brun G.L., Bernier M., Losier R., Doe K., Jackman P., Lee H.B. Pharmaceutically active compounds in atlantic Canadian sewage treatment plant effluents and receiving waters and potential for environmental effects as measured by acute and chronic aquatic toxicity. Environ Toxicol Chem 2006, 25:2163-2170.
20. Bunch A.R., Bernot M.J. Distribution of nonprescription pharmaceuticals in central Indiana streams and effects on sediment microbial activity. Ecotoxicology 2011, 20(1):97-109. [Jan, Epub 2010 Oct 31].
21. Butterfield S. Dumping drugs put traces of meds in taps 2009, ACP Internist, [February, http://www.acpinternist.org/archives/2009/02/drugs.htm].
22. Cavenati S., Carvalho P.N., Almeida C.M., Basto M.C., Vasconcelos M.T. Simultaneous determination of several veterinary pharmaceuticals in effluents from urban, livestock and slaughterhouse wastewater treatment plants using a simple chromatographic method. Water Sci Technol 2012, 66(3):603-611.
23. Cleuvers M. Aquatic ecotoxity of pharmaceuticals including the assessment of combination effects. Toxicol Lett 2003, 142:185-194.
24. Cone E.J., Phelps B.A., Gorodetzky C.W. Urinary excretion of hydromorphone and metabolites in humans, rats, dogs, guinea pigs, and rabbits. J Pharm Sci 1977, 66(12):1709-1713. [Dec].
25. Crane M., Watts C., Boucard T. Chronic aquatic environmental risks from exposure to human pharmaceuticals. Sci Total Environ 2006, 367:23-41.
26. Daneshvar A., Aboulfadl K., Viglino L., Brozeus R., Sauve S., Madoux-Humery A.-S., et al. Evaluating pharmaceuticals and caffeine as indicators of fecal contamination in drinking water sources of the greater Montreal region. Chemosphere 2012, 88:131-139.
27. Daughton C.G. Cradle-to-cradle stewardship of drugs for minimizing their environmental disposition while promoting human health. I. Rationale for and avenues toward a green pharmacy. Environ Health Perspect 2003, 111:757-774.
28. Daughton C.G. Cradle-to-cradle stewardship of drugs for minimizing their environmental disposition while promoting human health. II. Drug disposal, waste reduction, and future directions. Environ Health Perspect 2003, 111:775-785.
29. Daughton C.G., Ruhoy I.S. Environmental footprint of pharmaceuticals: significance of factors beyond direct excretion to sewers. Environ Toxicol Chem 2009, 28:12-15.
30. Depriest A., Heltsley R., Black D.L., Cawthon B., Robert T., Moser F., et al. Urine drug testing of chronic pain patients. III. Normetabolites as biomarkers of synthetic opioid use. J Anal Toxicol 2010, 34(8):444-449. [Oct].
31. Dixit V., Hariparsad N., Li F., Desai P., Thummel K.E., Unadkat J.D. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab Dispos 2007, 35(10):1853-1859. [Oct, Epub 2007 Jul 16].
32. Dorfman R.I., Hamilton J.B. Urinary excretion of androgenic substances after intramuscular and oral administration of testosterone propionate to humans. J Clin Invest 1939, 18(1):67-71. [January].
33. Escher R.F., Baumgartner R., Keller M., Treyer K., Lienert J., McArdell C.S. Environmental toxicology and risk assessment of pharmaceuticals from hospital wastewater. Water Res 2011, 45:75-92.
34. Esteban S., Valcarcel Y., Catal M., Castromil M.G. Psychoactive pharmaceutical residues in the watersheds of Galicia (Spain). Gac Sanit 2012, 26(5):457-459.
35. Fasola G., Aita M., Marini L., Follador A., Tosolini M., Mattioni L., et al. Drug waste minimisation and cost-containment in Medical Oncology: two-year results of a feasibility study. BMC Health Serv Res 2008, 8:70. [Apr 1].
36. Fed Regist Preventing the accumulation of surplus controlled substances at long term care facilities 2005, May 13;70(92):25462-6, Final rule, Drug Enforcement Administration (DEA).
37. Fent K., Weston A.A., Caminada D. Ecotoxicology of human pharmaceuticals. Aquat Toxicol 2006, 76:122-159.
38. Fernández C., Carbonell G., Babín M. Effects of individual and a mixture of pharmaceuticals and personal-care products on cytotoxicity, EROD activity and ROS production in a rainbow trout gonadal cell line (RTG-2). Appl Toxicol 2012, [Jun 21]. 10.1002/jat.2752.
39. Ferrari F., Gallipoli A., Balderacchi M., Ulaszewska M.M., Capri E., Trevisan M. Exposure of the main Italian river basin to pharmaceuticals. J Toxicol 2011, 989270.
40. Ferrer I., Zweigenbaum J.A., Thurman M.E. Analysis of 70 Environmental Protection Agency priority pharmaceuticals in water by EPA Method 1694. J Chromatogr 2010, 1217:5674-5686.
41. Flaherty C.M., Dodson S.I. Effects of pharmaceuticals on Daphnia survival, growth, and reproduction. Chemosphere 2005, 61:200-207.
42. Fram M.S., Belitz K. Occurance and concentrations of pharmaceutical compounds in groundwater used for public drinking-water supply in California. Sci Total Environ 2011, 409:3409-3417.
43. Fung E.Y., Leung B. Do automated dispensing machines improve patient safety?. Can J Hosp Pharm 2009, 62(6):516-519.
44. Giglio J., Colello A.D. Letter to nursing homes regarding fentanyl diversion and disposal guidelines 2001, State of New York Department of Health, 433 River Street, Troy, NY 12130, [November 8].
45. Giglio J., Heigel F. Letter to hospitals and class 3 facilities regarding fentanyl diversion and disposal guidelines 2001, State of New York Department of Health, 433 River Street, Troy, NY 12130, [October 4].
46. Glassmeyer S.T., Hinchey E.K., Boehme S.E., Daughton C.G., Ruhoy I.S., Conerly O., et al. Disposal practices for unwanted residential medications in the United States. Environ Int 2009, 35(3):566-572. [Apr].
47. Grung M., Källqvist T., Sakshaug S., Skurtveit S., Thomas K.V. Environmental assessment of Norwegian priority pharmaceuticals based on the EMEA guideline. Ecotoxicol Environ Saf 2008, 71(2):328-340. [Oct, Epub 2007 Dec 18].
48. Hall W., Prichard J., Kirkbride P., Bruno R., Thai P.K., Gartner C., et al. An analysis of ethical issues in using wastewater analysis to monitor illicit drug use. Addiction 2012, 107(10):1767-1773. [Oct, Epub 2012 May 8]. 10.1111/j.1360-0443.2012.03887.x.
49. Hedgespeth M.L., Sapozhnikova Y., Pennington P., Clum A., Fairey A., Wirth E. Pharmaceuticals and personal care products (PPCPs) in treated wastewater discharges into Charleston Harbor, South Carolina. Sci Total Environ 2012, 437C:1-9. [Aug 16].
50. Herring M.E., Shah S.K., Shah S.K., Gupta A.K. Current regulations and modest proposals regarding disposal of unused opioids and other controlled substances. J Am Osteopath Assoc 2008, 108(7):338-343. [Jul].
51. Hope B.K., Stone D., Fuji T., Gensemer R.W., Jenkins J. Meeting the challenge of identifying persistent pollutants at the state level. Integr Environ Assess Manag 2010, 6(4):735-748. [Oct].
52. Houlihan K.P.G., Mitchell R.G., Flapan A.D., Steedman D.J. Excessive morphine requirements after prehospital nalbuphine analgesia. J Accid Emerg Med 1999, 16:29-31.
53. Huggett D.B., Brooks B.W., Peterson B., Foran C.M., Schlenk D. Toxicity of select beta adrenergic receptor-blocking pharmaceutical (B-blockers) on aquatic organisms. Arch Environ Contam Toxicol 2002, 43:229-233.
54. Hyland R., Osborne T., Payne A., Kempshall S., Logan Y.R., Ezzeddine K., et al. In vitro and in vivo glucuronidation of midazolam in humans. Br J Clin Pharmacol 2009, 67(4):445-454. [Apr].
55. Jean J., Perrodin Y., Pivot C., Trepo D., Perraud M., Droguet J., et al. Identification and prioritization of bioaccumulable pharmaceutical substances discharged in hospital effluents. J Environ Manage 2012, 103:113-121. [Jul 30, Epub 2012 Mar 30].
56. Jelic A., Gros M., Petrovic M., Ginebreda A., Barcelo D. Occurrence and elimination of pharmaceuticals during conventional wastewater treatment. Emerging and Priority Pollutants in Rivers 2012, Springer-Verlag, Berlin. H. Guasch, A. Ginebreda, A. Geiszinger (Eds.).
57. Johnson K., Altman G.B. Managing controlled substances. Delmar's fundamental and advanced nursing skills 2004, Delmar Learning, Inc., Clifton Park, NY. 2nd ed. G.B. Altman (Ed.).
58. Jones O.H., Voulvoulis N., Lester J.N. Aquatic environmental assessment of the top 25 English prescription pharmaceuticals. Water Res 2002, 36:5013-5022.
59. Kaplan H.L., Busto U.E., Baylon G.J., Cheung S.W., Otton S.V., Somer G., et al. Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability. J Pharmacol Exp Ther 1997, 281(1):103-108. [Apr].
60. Kar S., Roy K. First report on interspecies quantitative correlation of ecotoxicity of pharmaceuticals. Chemosphere 2010, 81(6):738-747. [Oct, Epub 2010 Aug 9].
61. Khandelwal N., Duncan I., Ahmed T., Rubinstein E., Pegus C. Impact of clinical oral chemotherapy program on wastage and hospitalizations. Am J Manag Care 2011, 17(5 Spec No):e169-e173. [May 1].
62. Kidd K.A., Blanchfield P.J., Mills K.H., Palace V.P., Evans R.E., Lazorchak J.M., et al. Collapse of a fish population after exposure to a synthetic estrogen. PNAS 2007, 104:8897-8901.
63. Kim Y., Choi K., Jung J., Park S., Kim P.G., Park J. Aquatic toxicity of acetaminophen, carbamazepine, cimetidine, diltiazem and six major sulfonamides, and their potential ecological risks in Korea. Environ Int 2007, 33:370-375.
64. Kolpin D.W., Furlong E.T., Meyer M.T., Thurman E.M., Zaugg S.D., Barber L.B., et al. Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams 1999-2000: a national reconnaissance. Environ Sci Technol 2002, 36:1202-1211.
65. Kostich M.S., Lazorchak J.M. Risks to aquatic organisms posed by human pharmaceutical use. Sci Total Environ 2008, 389:329-339.
66. Kummerer K. Drugs in the environment: emission of drugs, diagnostic aids and disinfectants into wastewater by hospitals in relation to other sources - a review. Chemosphere 2001, 45:957-969.
67. Lacey C., Basha S., Morrissey A., Tobin J.M. Occurrence of pharmaceutical compounds in wastewater process streams in Dublin, Ireland. Environ Monit Assess 2012, 184(2):1049-1062. [Jan, Epub 2011 Apr 9].
68. Langford K.H., Thomas K.V. Determination of pharmaceutical compounds in hospital effluents and their contribution to wastewater treatment works. Environ Int 2009, 35:766-770.
69. Le Corre K.S., Ort C., Kateley D., Allen B., Escher B.I., Keller J. Consumption-based approach for assessing the contribution of hospitals towards the load of pharmaceutical residues in municipal wastewater. Environ Int 2012, 45:99-111. [Sep 15, Epub 2012 May 11].
70. Leonhart M., Rannazzisi J.T., Caverly M.W. Pharmacist's manual. An Informational outline of the controlled substances act. 2010 edition 2012, US DEA, Washington, DC, [www.deadiversion.usdoj.gov/pubs/manuals/pharm2/index.html accessed 9/24/2012].
71. Lewis J.H., Vine J.H. A simple and rapid method for the identification of zolpidem carboxylic acid in urine. J Anal Toxicol 2007, 31:195-199.
72. Li F.Y., Ort C., Gartner S., Pritchard J., Kirkbride P., Bruno R., et al. Refining the estimation of illicit drug consumptions from wastewater analysis: co-analysis of prescription pharmaceuticals and uncertainty assessment. Water Res 2011, 45:4437-4448.
73. Li A.C., Chovan J.P., Yu E., Zamora I. Update on hydrocodone metabolites in rats and dogs aided with a semi-automatic software for metabolite identification mass-metasite. Xenobiotica 2012, [Aug 30, Epub ahead of print]. http://dx.doi.org/10.3109/00498254.2012.715697.
74. Lienert J., Koller M., Konrad J., McArdell C.S., Schuwirth N. Multiple-criteria decision analysis reveals high stakeholder preference to remove pharmaceuticals from hospital wastewater. Environ Sci Technol 2011, 45(9):3848-3857. [May 1, Epub 2011 Mar 18].
75. Lin A.Y., Wang X.H., Lin C.F. Impact of wastewaters and hospital effluents on the occurrence of controlled substances in surface waters. Chemosphere 2010, 81(5):562-570.
76. Lo M.W., Schary W.L., Whitney C.C. The disposition and bioavailability of intravenous and oral nalbuphine in healthy volunteers. J Clin Pharmacol 1987, 27(11):866-873. [Nov].
77. Lorenzini K.I., Daali Y., Dayer P., Desmeules J. Pharmacokinetic-pharmacodynamic modelling of opioids in healthy human volunteers. A minireview. Basic Clin Pharmacol Toxicol 2012, 110(3):219-226. [Mar, Epub 2011 Nov 9]. 10.1111/j.1742-7843.2011.00814.x.
78. Madadi P., Hildebrandt D., Gong I.Y., Schwarz U.I., Ciszkowski C., Ross C.J., et al. Fatal hydrocodone overdose in a child: pharmacogenetics and drug interactions. Pediatrics 2010, 126(4):e986-e989. [Oct, Epub 2010 Sep 13].
79. Madden J.C., Enoch S.J., Hewitt M., Cronin M.T. Pharmaceuticals in the environment: good practice in predicting acute ecotoxicological effects. Toxicol Lett 2009, 185(2):85-101. [Mar 10, Epub 2008 Dec 9].
80. Mankes R.F. Propofol wastage in anesthesia. Anesth Analg 2012, 114(5):1091-1092. [May, Epub 2012 Mar 13].
81. Moldovan Z., Chira R., Alder A.C. Environmental exposure of pharmaceuticals and musk fragrances in the Somes River before and after upgrading the municipal wastewater treatment plant Cluj-Napoca, Romania. Environ Sci Pollut Res Int 2009, 16(Suppl. 1):S46-S54. [Aug].
82. Nava-Ocampo A.A., Alarcón-Almanza J.M., Moyao-García D., Ramírez-Mora J.C., Salmerón J. Undocumented drug utilization and drug waste increase costs of pediatric anesthesia care. Fundam Clin Pharmacol 2004, 18:107-112.
83. OECD Ecological categorization results from the Canadian domestic substance list 2012, Organisation for Economic Co-operation and Development, Paris, France, [http://webnet.oecd.org/ccrweb/ChemicalDetails.aspx?ChemicalID=32A0E165-3BE4-4B7F-961A-119B8130EE67 accessed 9/19/2012a].
84. OECD Ecological categorization results from the Canadian domestic substance list 2012, Organisation for Economic Co-operation and Development, Paris, France, [http://webnet.oecd.org/ccrweb/ChemicalDetails.aspx?ChemicalID=D79B0AD2-FC6E-46A9-B275-1018105B8B48 accessed 9/19/2012b].
85. OECD Ecological categorization results from the Canadian domestic substance list 2012, Organisation for Economic Co-operation and Development, Paris, France, [http://webnet.oecd.org/ccrweb/ChemicalDetails.aspx?ChemicalID=7184D9A0-11A2-4CBB-B2C7-771B80E86E03 accessed 9/19/2012c].
86. ONDCP Office of National Drug Control Policy Proper disposal of prescription drugs February, [accessed 9/12/2012]. http://www.whitehousedrugpolicy.gov.
87. Ort C., Lawrence M.G., Reungoat J., Eaglesham G., Carter S., Keller J. Determining the fraction of pharmaceutical residues in wastewater originating from a hospital. Water Res 2010, 44(2):605-615. [Jan, Epub 2009 Aug 5].
88. Page Alfred N. Translation of Manuale di economia politica 1971, A.M. Kelley, [ISBN 978-0-678-00881-2].
89. Pal R., Megharaj M., Kirkbride K.P., Naidu R. Illicit drugs and the environment - a review. Sci Total Environ 2012, [Jun 21]. http://dx.doi.org/10.1016/j.scitotenv.2012.05.086.
90. Parrott J.L., Bennie D.T. Life-cycle exposure of fathead minnows to a mixture of six common pharmaceuticals and triclosan. J Toxicol Environ Health 2009, 79:633-641.
91. Phillips P.J., Smith S.G., Kolpin D.W., Zaugg S.D., Buxton H.T., Furlong E.T., et al. Pharmaceutical formulation facilities as sources of opioids and other pharmaceuticals to wastewater treatment plant effluents. Environ Sci Technol 2010, 44:4910-4916.
92. Postigo C., de Alda MJ Lopez, Barrelo D. Drugs of abuse and their metabolites in the Elbro river basin: occurrence in sewage and surface water, sewage treatment plants removal efficiency, and collective drug usage estimation. J Environ Int 2010, 36:75-84.
93. Quinn B., Gagne F., Blaise C. An investigation into the acute and chronic toxicity of eleven pharmaceuticals and their solvents found in wastewater effluent on the cnidarian, Hydra attenuate. Sci Total Environ 2008, 389:306-314.
94. Radjenovic J., Petrovic M., Barcelo D. Analysis of pharmaceuticals in wastewater and removal using a membrane bioreactor. Anal Bioanal Chem 2007, 387:1365-1377.
95. Ramírez J., Innocenti F., Schuetz E.G., Flockhart D.A., Relling M.V., Santucci R., et al. CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab Dispos 2004, 32(9):930-936. [Sep].
96. Rannazzisi JT, Caverly MW. Practitioner's Manual. An Informational Outline of the Controlled Substances Act. edition. Washington, DC: US DEA, 2006.
97. Reidy L., Nolan B., Ramos A.R., Walls H.C., Steele B.W. Zolpidem urine excretion profiles and cross-reactivity with ELISA(®) kits in subjects using Zolpidem or Ambien(®) CR as a prescription sleep aid. J Anal Toxicol 2011, 35(5):294-301. [Jun].
98. Richards S.M., Cole S.E. A toxicity and hazard assessment of fourteen pharmaceuticals to Xenopus laevis larvae. Ecotoxicology 2006, 15:647-656.
99. Robbins J., Garman A.N., Song P.H., McAlearney A.S. How high-performance work systems drive health care value: an examination of leading process improvement strategies. Qual Manag Health Care 2012, 21(3):188-202. [Jul-Sep].
100. Rodriguez-Mozaz S., Weinberg H.S. Meeting report: Pharmaceuticals in water - an interdisciplinary approach to a public health challenge. Environ Health Perspect 2010, 118:1016-1020.
101. Roy K., Esaki M.D., Macario Alex Wastage of supplies and drugs in the operating room. Medscape Anesthesiology 2009.
102. Ruhoy I.S., Daughton C.G. Types and quantities of leftover drugs entering the environment via disposal to sewage - revealed by coroner records. Sci Total Environ 2007, 388:137-148.
103. Sailaukhanuly Y., Zhakupbekova A., Amutova F., Carlsen L. On the ranking of chemicals based on their PBT characteristics: comparison of different ranking methodologies using selected POPs as an illustrative example. Chemosphere 2013, 90(1):112-117.
104. Salva P., Costa J. Clinical pharmokinetics and pharmacodynamics of zolpidem. Therapeutic implications. Clin Pharmacokinet 1995, 29:142-153.
105. Sanchez W., Sremski W., Piccini B., Palluel O., Maillot-Marechal E., Betoulle S., et al. Adverse effects in wild fish living downstream from pharmaceutical manufacture discharges. Environ Int 2011, 37:1342-1348.
106. Sanderson H., Johnson D.J., Wilson C.J., Brain R.A., Solomon K.R. Probabilistic hazard assessment of environmentally occurring pharmaceuticals toxicity to fish, daphnids, and algae by ECOSAR screening. Toxicol Lett 2003, 144:383-395.
107. Santos J.J., Aparicio I., Callejon M., Alonso E. Occurrence of pharmaceutically active compounds during 1-year period in wastewaters from four wastewater treatment plants in Seville (Spain). J Hazard Mater 2009, 164:1509-1516.
108. Sellin M.K., Snow D.D., Gustafson S.T., Erickson G.E., Kolok A.S. The endocrine activity of beef cattle wastes: do growth promoting steroids make a difference?. Aquat Toxicol 2009, 92:221-227.
109. Sellin M.K., Snow D.D., Schwartz M., Carte B.J., Kolok A.S. Agrichemicals in Nebraska, USA, watersheds: occurrence and endocrine effects. Environ Toxicol Chem 2009, 28:2443-2448.
110. Seo K.A., Bae S.K., Choi Y.K., Choi C.S., Liu K.H., Shin J.G. Metabolism of 1?- and 4-hydroxymidazolam by glucuronide conjugation is largely mediated by UDP-glucuronosyltransferases 1A4, 2B4, and 2B7. Drug Metab Dispos 2007, 38(11):13. [Nov, Epub 2010 Aug 16].
111. Sim W.J., Lee J.W., Lee E.S., Shin S.K., Hwang S.R., Oh J.E. Occurrence and distribution of pharmaceuticals in wastewater from households, livestock farms, hospitals and pharmaceutical manufactures. Chemosphere 2011, 82(2):179-186. [Jan, Epub 2010 Oct 30].
112. Smith M.L., Hughes R.O., Levine B., Dickerson S., Darwin W.D., Cone E.J. Forensic drug testing for opiates. VI. Urine testing for hydromorphone, hydrocodone, oxymorphone, and oxycodone with commercial opiate immunoassays and gas chromatography-mass spectrometry. J Anal Toxicol 1995, 19(1):18-26. [Jan-Feb].
113. Smolen A. Role of the pharmacist in proper medication disposal. US Pharm 2011, 36(7):52-55.
114. Soliman M.A., Pedersen J.A., Park H., Castaneda-Jimenez A., Stenstrom M.K., Suffet I.H. Human pharmaceuticals, antioxidants, and plasticizers in wastewater treatment plant and water reclamation plant effluents. Water Environ Res 2007, 79(2):156-167.
115. Stackelberg P.E., Furlong E.T., Meyer M.T., Zaugg S.D., Henderson A.K., Reissmann D.B. Persistence of pharmaceutical compounds and other organic wastewater contaminants in a conventional drinking-water treatment plant. Sci Total Environ 2004, 329:99-113.
116. Stackelberg P.E., Gibs J., Furlong E.T., Meyer M.T., Zaugg S.D., Lippincott R.L. Efficiency of conventional drinking-water-treatment processes in removal of pharmaceuticals and other organic compounds. Sci Total Environ 2007, 377:255-272.
117. Stambaugh J.E., Wainer I.W., Sanstead J.E., Hemphill D.M. The clinical pharmacology of meperidine-comparison of routes of administration. J Clin Pharmacol 1976, 245-256. [May-June].
118. Stonemetz J., Pham J.C., Necochea A.J., McGready J., Hody R.E., Martinez E.A. Reduction of regulated medical waste using lean sigma results in financial gains for hospital. Anesthesiol Clin 2011, 29(1):145-152. [Mar].
119. Stoner S. A new prescription: do not flush your unused drugs. Conservationist 2009, 14-16. http://www.dec.ny.gov/docs/administration_pdf/0409dontflush.pdf.
120. Straub J.O. Environmental risk assessment for new human pharmaceuticals in the European Union according to the draft guideline/discussion paper of January 2001. Toxicol Lett 2002, 135(3):231-237. [Oct 5].
121. Straub J.O., Gysel D., Kastl U., Klemmer J., Sonderegger M., Studer M., et al. Environmental risk assessment for ancillary substances in biotechnological production of pharmaceuticals. Environ Toxicol Chem 2012, 31(3):681-687. [Mar, Epub 2012 Feb 6]. 10.1002/etc.1733.
122. Strempel S., Scheringer M., Ng C.A., Hungerbühler K. Screening for PBT chemicals among the "existing" and "new" chemicals of the EU. Environ Sci Technol 2012, 46(11):5680-5687. [Jun 5, Epub 2012 May 11].
123. Stuer-Lauridsen F., Birkved M., Hansen L.P., Lützhøft H.C., Halling-Sørensen B. Environmental risk assessment of human pharmaceuticals in Denmark after normal therapeutic use. Chemosphere 2000, 40(7):783-793. [Apr].
124. Subedi B., Du B., Chambliss C.K., Koschorreck J., Rüdel H., Quack M., et al. Occurrence of pharmaceuticals and personal care products in German fish tissue: a national study. Environ Sci Technol 2012, 46(16):9047-9054. [Aug 21].
125. Tamtam F., Mercier F., Lebot D., Eurin J., Dinh Q.T., Clement M., et al. Occurrence and fate of antibiotics in the Seine River in various hydrological conditions. Sci Total Environ 2008, 393:84-95.
126. Terzic S., Senta I., Ahel M. Illicit drugs in wastewater of the city of Zagreb (Croatia) - estimation of drug abuse in a transitional country. Environ Pollut 2010, 158:2686-2693.
127. Thomaidis N.S., Asimakopoulos A.G., Bletsou A.A. Emerging contaminants: a tutorial mini-review. GlobalNEST J 2012, 14(1):72-79.
128. Toxnet: Hazardous Substances Data Bank (HSDB) A database of the National Library of Medicine's TOXNET system [accessed 9/19/2012]. http://toxnet.nlm.nih.gov.
129. US EPA Clean Air Act February 17, [access 9/27/2012]. http://www.epa.gov/air/caa/.
130. US FDA Disposal of Unused Medicines: What You Should Know List revised: January, [Accessed 9/17/2012]. http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/EnsuringSafeUseofMedicine/SafeDisposalofMedicines/ucm186187.htm.
131. US Office of National Drug Control Policy Proper disposal of Prescription drugs February, 2007, ONDCP, Washington, DC 20503, http:www.whitehousedrugpolicy.gov.
132. Valtier S., Bebarta V.S. Excretion profile of hydrocodone, hydromorphone and norhydrocodone in urine following single dose administration of hydrocodone to healthy volunteers. J Anal Toxicol 2012, 36(7):507-514. [Sep, Epub 2012 Jul 10].
133. Verlicchi P., Al Aukidy M., Zambello E. Occurrence of pharmaceutical compounds in urban wastewater: removal, mass load and environmental risk after a secondary treatment-a review. Sci Total Environ 2012, 429:123-155. [Jul 1].
134. von der Ohe P.C., Dulio V., Slobodnik J., De Deckere E., Kühne R., Ebert R.U., et al. A new risk assessment approach for the prioritization of 500 classical and emerging organic microcontaminants as potential river basin specific pollutants under the European Water Framework Directive. Sci Total Environ 2011, 409(11):2064-2077. [May 1].
135. Weinger M.B. Drug wastage contributes significantly to the cost of routine anesthesia care. J Clin Anesth 2001, 13:491-497.
136. Winker M., Faika D., Gulyas H., Otterpohl R. A comparison of human pharmaceutical concentration in raw municipal wastewater and yellow water. Sci Total Environ 2008, 399:96-104.
137. Yeh B.T. Legal issues relating to the disposal of dispensed controlled substances. Cong Res Serv 2010, R40548. [October 19, at: https://opencrs.com/document/R40548/ accessed 9/17/2012].
138. Yoo Y.C., Chung H.S., Kim I.S., Jin W.T., Kim M.K. Determination of nalbuphine in drug abusers' urine. J Anal Toxicol 1995, 19(2):120-123. [Mar-Apr].
139. Zarfl C., Hotopp I., Kehrein N., Matthies M. Identification of substances with potential for long-range transport as possible substances of very high concern. Environ Sci Pollut Res Int 2012, 19(8):3152-3161. [Sep. Epub 2012 Jul 1].
140. Zuccato E., Chiabrando C., Castilioni S., Bagnati R., Fanelli R. Estimating community drug abuse by wastewater analysis. Environ Health Perspect 2008, 116:1027-1032.